PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26460717-8	2016	In particular PDE3A was specifically activated, as milrinone reversed cAMP reduction by 2-AG.	Milrinone	51-60	phosphodiesterase 3A	Homo sapiens	14-19	
28959341-9	2016	The activity of the expressed PDE3A and PDE3B proteins were investigated by cAMP and cGMP dsgradation with or without addition of milrinone, a potent and selective PDE inhibitor.	Milrinone	130-139	phosphodiesterase 3A	Homo sapiens	30-35	
28959341-13	2016	Furthermore, degradation of cAMP and cGMP through the activity of PDE3A and PDE3B was suppressed following to the addition of milrinone.	Milrinone	126-135	phosphodiesterase 3A	Homo sapiens	66-71	
7860763-11	1995	Milrinone (10 microM) induced a strong stimulation of ICa (approximately 150%), demonstrating that cGI-PDE controls the amplitude of basal ICa in this tissue.	Milrinone	0-9	phosphodiesterase 3A	Homo sapiens	99-106	
10859452-7	2000	The distribution pattern of the mRNA for the isoenzymes PDE3A and PDE5A may explain the pharmacological effects as well as the side effects of milrinone and sidenafil.	Milrinone	143-152	phosphodiesterase 3A	Homo sapiens	56-61	
15354266-8	2004	Two inhibitors of PDE3A are used in clinical medicine: milrinone and cilostazol.	Milrinone	55-64	phosphodiesterase 3A	Homo sapiens	18-23	
1652182-2	1991	Milrinone and OPC 3911, inhibitors of a cGMP-inhibited cAMP phosphodiesterase (cGI-PDE), were shown to have distinct vasodilator actions.	Milrinone	0-9	phosphodiesterase 3A	Homo sapiens	40-77	
1652182-2	1991	Milrinone and OPC 3911, inhibitors of a cGMP-inhibited cAMP phosphodiesterase (cGI-PDE), were shown to have distinct vasodilator actions.	Milrinone	0-9	phosphodiesterase 3A	Homo sapiens	79-86